James F. Tessmer's most recent trade in Lexicon Pharmaceuticals Inc was a trade of 12,000 Common Stock done at an average price of $6.9 . Disclosure was reported to the exchange on March 15, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Sale of securities on an exchange or to another person at price $ 6.92 per share. | 15 Mar 2021 | 12,000 | 71,766 (0%) | 0% | 6.9 | 83,100 | Common Stock |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.31 per share. | 15 Mar 2021 | 12,000 | 83,766 (0%) | 0% | 3.3 | 39,720 | Common Stock |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 12,000 | 50,980 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Sale of securities on an exchange or to another person at price $ 6.90 per share. | 15 Mar 2021 | 10,912 | 71,766 (0%) | 0% | 6.9 | 75,340 | Common Stock |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 13,997 | 27,993 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 13,997 | 93,443 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 10,765 | 82,678 (0%) | 0% | 7.2 | 77,400 | Common Stock |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 8,836 | 8,837 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 8,836 | 79,446 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,213 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,213 | 70,610 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,270 | 66,397 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,270 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 24,340 | 24,340 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | James F. Tessmer | VP, Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 16,230 | 16,230 | - | - | Restricted Stock Units |